Jonas Salk replied, "Well, the people I would say. There is no patent. Could you patent the sun?" The vaccine is calculated to be worth $7 billion had it been patented. However, lawyers from the National Foundation for Infantile Paralysis did look into the possibility of a patent, but ultimately determined that the vaccine was not a patentable invention because of prior art. Salk served on the board of directors of the John D. and Catherine T. MacArthur Foundation. Author Jon Cohen noted, "Jonas Salk made scientists and journalists alike go goofy. As one of the only living scientists whose face was
Influenza vaccine sera (chiefly against what we now call "Hemophilus influenzae"—a name derived from the fact that it was originally considered the etiological agent—and several types of pneumococci). Only one therapeutic measure, transfusing blood from recovered patients to new victims, showed any hint of success." In 1931, viral growth in embryonated hens' eggs was reported by Ernest William Goodpasture and colleagues at Vanderbilt University. The work was extended to growth of influenza virus by several workers, including Thomas Francis, Jonas Salk, Wilson Smith and Macfarlane Burnet, leading to the first experimental influenza vaccines. In the 1940s, the US military developed the first